2111. FMT Outcomes in Immunocompetent and Immunocompromised Patients: A Single Center Experience
Session: Poster Abstract Session: Clostridium difficile: Therapeutics
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • ID Week Poster TGH V2.pdf (370.8 kB)
  • Background: 

    Clostridium difficile infection (CDI) is a major infectious disease focus, as it has become increasingly severe with an inclination to recur in up to 20% of patients. Fecal microbiota transplantation (FMT) has been used with success in various patient populations; however, there is limited literature for its use in the immunocompromised population, including solid organ transplant (SOT) patients. We conducted a retrospective study of FMT for recurrent CDI in immunocompetent and immunocompromised patients to review outcomes at our center, with a focus on identifying risk factors for FMT failure in SOT patients.

    Methods: 

    Adult patients 18 years of age and older who received FMT for recurrent CDI from May 2014 through October 2015 were eligible for inclusion in the study. Patients were excluded from the study if they received FMT for an indication other than recurrent CDI. FMT was conducted using universal banked frozen stool via naso-duodenal tube in patients with recurrent CDI of 3 or more episodes per our institutional protocol.

    Results: 

    Thirteen patients were included in the analysis, with ages ranging from 21 to 76 and a median age of 69 years. Six patients were immunocompetent and 7 were immunocompromised. Of the immunocompromised patients, 6 patients had a history of SOT and were primarily abdominal organs. All immunocompetent patients experienced success with FMT while 3 immunocompromised SOT patients experienced failure. In our patients who failed a single FMT, they began to experience recurrent symptoms within the first few weeks post-FMT. Two of these failed patients had a second FMT, which was successful in one patient and failed in the second patient. One SOT patient underwent sequential FMT with success. No adverse events were noted with FMT administration. Predictors of FMT failure in SOT patients included advanced age and prolonged duration of immunosuppression.

    Conclusion: 

    This study highlights the successful use of FMT for recurrent CDI in immunocompetent patients with variable efficacy in immunocompromised patients. Additionally, FMT was shown to be safe and well tolerated across our study population. The use of sequential FMT therapy in the SOT population may be considered to optimize restoration of intestinal microflora.

    Kristen Zeitler, PharmD1, Ripal Joshi, PharmD1, Jose Montero, M.D.2 and Sally Alrabaa, MD2, (1)Department of Pharmacy, Tampa General Hospital, Tampa, FL, (2)Infectious Diseases and International Medicine, University of South Florida, Tampa, FL

    Disclosures:

    K. Zeitler, None

    R. Joshi, None

    J. Montero, None

    S. Alrabaa, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.